• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

How eClinicalWorks Agentic AI Is Helping Revenue Cycle Leaders Improve Financial Performance
  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Life Sciences
  • Investments
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage

Mount Sinai Researchers Use AI and Lab Data to Predict Genetic Disease Risk

by Fred Pennic 08/28/2025 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print
Image credit:  Icahn School of Medicine at Mount Sinai 

What You Should Know:

– Researchers at the Icahn School of Medicine at Mount Sinai have developed a new method using artificial intelligence (AI) and routine lab tests to determine the likelihood that a patient with a rare DNA mutation will actually develop a disease. 

– The concept is known in genetics as penetrance. The findings were published in the August 28 online issue of the journal Science.  

A More Accessible Approach to Genetic Risk

Traditional genetic studies often use a simple yes/no diagnosis to classify patients, but many diseases, such as high blood pressure, diabetes, or cancer, do not fit into these binary categories. The Mount Sinai researchers trained AI models to quantify disease on a spectrum, which offers a more nuanced view of how disease risk plays out in real life.

The research team set out to solve this problem by using AI and real-world lab data, such as cholesterol levels and blood counts, which are already part of most medical records. According to Dr. Ron Do, senior study author and the Charles Bronfman Professor in Personalized Medicine at Mount Sinai, this new method is a “much more nuanced, scalable, and accessible way to support precision medicine”. He added that it is especially useful when dealing with rare or ambiguous findings.

Research Approach/Protocol

Using more than 1 million electronic health records (EHRs), the researchers built AI models for 10 common diseases. They then applied these models to people with rare genetic variants to generate a “ML penetrance” score between 0 and 1 that reflects the likelihood of developing a disease. A higher score, closer to 1, suggests a variant may be more likely to contribute to the disease, while a lower score indicates minimal or no risk.

Some of the results were surprising, according to the investigators, as variants previously labeled as “uncertain” showed clear disease signals, while others thought to cause disease had little effect in real-world data.

Dr. Iain S. Forrest, lead study author, noted that while the AI model is not meant to replace clinical judgment, it could potentially serve as an important guide when test results are unclear. For example, a high score for a variant associated with Lynch syndrome could trigger earlier cancer screening, while a low score could help avoid unnecessary worry or overtreatment.

AI Model Expansion Plans

The team is now working to expand the model to include more diseases, a wider range of genetic changes, and more diverse populations. They also plan to track how well these predictions hold up over time and whether early action can make a difference.

This work was supported in part by the following grants: National Institute of General Medical Sciences of the National Institutes of Health (NIH) (T32-GM007280); the National Institute of General Medical Sciences of the NIH (R35-GM124836); the National Institute of Diabetes and Digestive and Kidney Diseases (U24-DK062429); the National Human Genome Research Institute of the NIH (R01-HG010365); the National Institute of General Medical Sciences of the NIH (R35-GM138113); and the National Institute of Diabetes and Digestive and Kidney Diseases (U24-DK062429). 

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tagged With: Artificial Intelligence, Mount Sinai

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Insights

How eClinicalWorks Agentic AI Is Helping Revenue Cycle Leaders Improve Financial Performance

Most-Read

Innovaccer-CHIME 2030 Survey Reveals AI Will Automate Nearly Two-Thirds of Administrative Work and Do 3x the Work With the Same Staff

Innovaccer-CHIME 2030 Survey Reveals AI Will Automate Nearly Two-Thirds of Administrative Work and Do 3x the Work With the Same Staff

CB Insights’ 2026 Digital Health 50 Reveals How Agentic AI Is Becoming the Clinical Provider and Medication Access Engine

Oura Acquires Counsel Health for $625M: Scaling Continuous Biometrics into On-Demand Medical Care

M&A: Oura Acquires Counsel Health for $625M: Scaling Continuous Biometrics into On-Demand Medical Care

WittKieffer 2026 Healthcare CIO Survey: 82% Sit on Executive Teams, Yet Only 36% Have Formal Succession Plans

WittKieffer 2026 Healthcare CIO Survey: 82% Sit on Executive Teams, Yet Only 36% Have Formal Succession Plans

CVS Rebrands Health Services Segment, Launches Model for Retail Pharmacy Reimbursement

CVS Health Formalizes Tax-Free Split-Off to Carve Out CVS Pharmacy by 2028

SAMHSA and ONC Invest $20M in Behavioral Health IT Initiative

ONC Finalizes HTI-5 Deregulatory Rule to Cut $1.55B in Health IT Compliance and Accelerate FHIR APIs

Redesign Health Merges with Sheba Medical Center’s ARC Global and Agrees to Acquire AVIA

Redesign Health Merges with Sheba Medical Center’s ARC Global and Agrees to Acquire AVIA

Sword Acquires Headspace in All-Cash Deal Worth Up to $300M to Unify Physical and Mental AI Care

M&A: Sword Acquires Headspace in All-Cash Deal Worth Up to $300M to Unify Physical and Mental AI Care

M&A: Francisco Partners to Acquire Weave in $650M Take-Private Deal

M&A: Francisco Partners to Acquire Weave in $650M Take-Private Deal

Epic Launches One-Click Care Everywhere Diagnostic Image Exchange

Epic Launches One-Click Care Everywhere Diagnostic Image Exchange

Secondary Sidebar

Footer

Company

  • About Us
  • 2026 Editorial Calendar
  • Advertise with Us
  • Reprints and Permissions
  • Op-Ed Submission Guidelines
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2026. HIT Consultant Media. All Rights Reserved. Privacy Policy |